Co-Authors
This is a "connection" page, showing publications co-authored by JAMES C YAO and AHMED KASEB.
Connection Strength
3.294
-
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9:773-80.
Score: 0.548
-
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist. 2024 Jun 03; 29(6):e803-e810.
Score: 0.243
-
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2024; 11:455-461.
Score: 0.239
-
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology. 2023; 101(11):730-737.
Score: 0.231
-
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
Score: 0.220
-
Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022; 12:986305.
Score: 0.217
-
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
Score: 0.207
-
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
Score: 0.201
-
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292.
Score: 0.198
-
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr 13; 12(8):756-766.
Score: 0.196
-
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
Score: 0.189
-
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
Score: 0.174
-
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
Score: 0.151
-
Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
Score: 0.144
-
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:1-7.
Score: 0.137